The Ingredients: Triamcinolone
Dosage Form and Administration: Tablet; Oral
U Drug Trade Name: Aristocort
Firm: Astellas
Strength: 16MG
New Drug Application Type: N
The Drug Application Number: 11161
Medicine Product Number: 10
Approval Date: 1/1/1982
Reference Listed Drug: No
Type: DISCN
Applicant Full Name: Astellas Pharma Us Inc
Local Number: 44460

Cognitive Behavioral Therapy

Doctors developed cognitive behavioral therapy as a method of preventing relapse when treating a patient with problem drinking. Later cognitive doctors adapted behavioral therapies to help individuals addicted to cocaine. Cognitive behavioral strategies stem from the theory that learning processes play a critical role in the development of maladaptive behavioral patterns. Individuals learn to identify and correct problematic behaviors by applying a range of different skills to stop drug abuse and to address other problems that often exist with it. Therapies for treating alcohol, marijuana, cocaine, methamphetamine and nicotine exist. Cognitive behavioral therapy generally consists of a collection of strategies that aim to enhance self control. Specific techniques include: exploring the positive and negative consequences of continued use, monitoring oneself to recognize drug cravings early on and to identify risky situations for use and developing strategies for coping with and avoiding risky situations associated with the desire to use. A central element of cognitive behavioral therapy is anticipating problems and helping patients develop effective coping strategies. Research indicates that the skills individuals learn through cognitive behavioral approaches remain in use after the completion of treatment. In several studies, most people who choose a cognitive behavioral approach to recovery showed progress throughout the following year. Current research focuses on how to produce effects that are even more powerful by combining cognitive behavioral therapy with medications for drug abuse and with other types of behavioral therapies. Researchers are also evaluating how best to train treatment providers to deliver cognitive behavioral therapy.

Vitiligo

Vitiligo or leukoderma is a chronic skin disease that causes loss of pigment, resulting in irregular pale patches of skin. The precise cause of vitiligo is complex and not fully understood. There is some evidence that suggests a combination of autoimmune, genetic and environmental factors causes vitiligo. The incidence of vitiligo worldwide is between one and two percent. According to the Diseases Database, the disorder appears in of areas of macular depigmentation, commonly on extensor aspects of extremities, on the face or neck, and in skin folds. The age of onset is often in young adulthood and the condition tends to progress gradually with lesions enlarging and extending until a quiescent state is reached. Half of the people living with vitiligo develop patches of de-pigmented skin appearing on extremities before their 20s. The patches may grow, shrink or remain constant in size. Patches often occur symmetrically across both sides on the body. Occasionally small areas may re-pigment as they are recolonised by melanocytes. The location of vitiligo affected skin changes over time, with some patches re-pigmenting and de-pigmenting.

Sensitive Skin

Sensitive skin is a thin or a fine-textured skin that reacts quickly to both heat and cold and therefore sunburns and windburns easily. It is commonly dry, delicate and prone to allergic reactions. Temperature changes, some detergents, cosmetics and alcohol (used on the skin) can all cause irritation, leaving the skin red and blotchy, with visible surface veins. The skin is the largest organ of the human body. Its size (about 20 square feet on an average sized adult) and external location make it susceptible to a wide variety of diseases, disorders, discolorations and growths, as well as to damage from the environment and the aging process.